Target other gene point mutations: HER2 and rare EGFR mutations

Federico Cappuzzo (Livorno, Italy)

Source: ERS Research Seminar
Number: 7
Disease area: Thoracic oncology

PDF journal article, handout or slidesPDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Federico Cappuzzo (Livorno, Italy). Target other gene point mutations: HER2 and rare EGFR mutations. ERS Research Seminar

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Target gene rearrangements: ALK, ROS and RET
Source: ERS Research Seminar
Year: 2015

EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype
Source: Eur Respir J 2014; 43: 872-883
Year: 2014



Are KRAS mutations druggable?
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019



Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients
Source: Eur Respir Rev 2014; 23: 390-392
Year: 2014


KRAS & TP53 mutations cause malignant mesothelioma
Source: ERS Lung Science Conference 2017
Year: 2017

Mapping of KRAS mutations during chemical carcinogenesis
Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases
Year: 2020


Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib?
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008


LSC - 2017 - KRAS & TP53 mutations cause malignant mesothelioma
Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside
Year: 2017

Diagnostic utility of PNA-LNA PCR clamp method for detection of EGFR exon 19 deletions and exon 21 codon L858 mutations in NSCLC samples with low tumor cells content
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012

Variable phenotype associated with SP-C gene mutations: fatal case with the I73T mutation
Source: Eur Respir J 2004; 24: 1072-1073
Year: 2004


Sarcoidosis is associated with a truncating splice site mutation in the BTNL2 gene
Source: Eur Respir J 2005; 26: Suppl. 49, 468s
Year: 2005

The analysis of CHEK2 gene mutation in small cell lung cancer
Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases
Year: 2021

Frequency and clinical-tomographic characterization of NSCLC with T790M mutation to TKI progression.
Source: International Congress 2019 – Diagnosis of lung cancer
Year: 2019


Detection of k-ras codon 12 mutations in human lung tumour tissue by REMS-PCR
Source: Eur Respir J 2001; 18: Suppl. 33, 233s
Year: 2001

EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013


NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016


p53 gene mutations in lung cancer in Korean
Source: Eur Respir J 2005; 26: Suppl. 49, 327s
Year: 2005

Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort
Source: Eur Respir J 2012; 40: 177-184
Year: 2012



Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required?
Source: Eur Respir J 2014; 44: 269-270
Year: 2014


Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required?
Source: Eur Respir J 2014; 44: 270-271
Year: 2014